SpliceBio has successfully raised $135 million in Series B funding to advance its gene therapy program SB-007 for Stargardt disease and expand its pipeline of genetic medicines.

Target Company Overview

SpliceBio, a clinical-stage genetic medicines company headquartered in Barcelona, Spain, is pioneering a groundbreaking approach known as Protein Splicing to address diseases arising from mutations in large genes. The company's flagship gene therapy candidate, SB-007, aims to treat Stargardt disease—a hereditary retinal disorder characterized by progressive vision loss and blindness due to mutations in the ABCA4 gene. This disease currently has no approved treatments. SB-007 is notable for being the first dual adeno-associated viral (AAV) gene therapy to receive regulatory clearance from the FDA for clinical development.

The recent $135 million Series B financing, co-led by EQT Life Sciences and Sanofi Ventures, will facilitate the advancement of SB-007 through its Phase 1/2 ASTRA clinical trial and the observational POLARIS study. The funds will also bolster SpliceBio’s broader pipeline, which encompasses several gene therapies targeting a variety of conditions in ophthalmology, neurology, and other undisclosed therapeutic areas.

Industry Overview

The landscape for genetic medicines in Spain has evolved significantly in recent years, driven by advancements in gene therapy technologies and an increasing focus on rare genetic disorders. With a growing number of biotech firms dedicat